Immunome Inc. (IMNM) insider trading.
In Q3 2026, insiders at Immunome Inc. reported 29 non-derivative transactions on 15 Forms 3, 4 and 5: 0 open-market purchases and 16 sales worth $13.8M.
- Transactions
- 29
- Purchases (P)
- 0
- Sales (S)
- 16
- Net shares, P minus S
- -580,510
- Insiders
- 8
- Last filed
- 2026-09-15
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Barchas Isaac | Director | 10 | 0 | 10 |
| Horn Kinney | Officer · CHIEF BUSINESS OFFICER | 6 | 0 | 2 |
| Lechleider Robert | Officer · Chief Medical Officer | 5 | 0 | 3 |
| Higgins Jack | Officer · Chief Scientific Officer | 4 | 0 | 1 |
| Siegall Clay B | Director, Officer · President and CEO | 1 | 0 | 0 |
| Stoneman Sandra G. | Officer · CHIEF LEGAL OFFICER & GC | 1 | 0 | 0 |
| Rosett Max | Officer · Chief Financial Officer | 1 | 0 | 0 |
| Tsai Philip | Officer · Chief Technical Officer | 1 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-11 | Higgins Jack | G (D) | 8,800 | $0 | 56,250 | Form 4 |
| 2026-09-11 | Higgins Jack | S (D) | 13,200 | $25.32 | 65,050 | Form 4 |
| 2026-09-11 | Higgins Jack | M (A) | 18,000 | $1.35 | 78,250 | Form 4 |
| 2026-08-12 | Barchas Isaac | S (D) | 11,048 | $27.25 | 92,211 | Form 4 |
| 2026-08-11 | Barchas Isaac | S (D) | 62,291 | $26.23 | 0 | Form 4 |
| 2026-08-10 | Barchas Isaac | S (D) | 10,125 | $26.07 | 62,291 | Form 4 |
| 2026-08-07 | Barchas Isaac | S (D) | 15,248 | $26.06 | 72,416 | Form 4 |
| 2026-08-06 | Barchas Isaac | S (D) | 20,840 | $26.06 | 87,664 | Form 4 |
| 2026-08-04 | Horn Kinney | M (A) | 40,250 | $10.6 | 90,616 | Form 4 |
| 2026-08-04 | Horn Kinney | M (A) | 50,366 | $12.92 | 50,366 | Form 4 |
| 2026-08-04 | Horn Kinney | S (D) | 90,616 | $25.09 | 0 | Form 4 |
| 2026-07-23 | Siegall Clay B | A (A) | 180,000 | $0 | 870,704 | Form 4 |
| 2026-07-23 | Stoneman Sandra G. | A (A) | 38,250 | $0 | 43,805 | Form 4 |
| 2026-07-23 | Horn Kinney | A (A) | 31,250 | $0 | 31,250 | Form 4 |
| 2026-07-23 | Higgins Jack | A (A) | 38,250 | $0 | 60,250 | Form 4 |
| 2026-07-23 | Rosett Max | A (A) | 47,250 | $0 | 101,287 | Form 4 |
| 2026-07-23 | Lechleider Robert | A (A) | 54,000 | $0 | 69,805 | Form 4 |
| 2026-07-23 | Tsai Philip | A (A) | 38,250 | $0 | 81,550 | Form 4 |
| 2026-07-07 | Horn Kinney | M (A) | 1,092 | $12.92 | 1,092 | Form 4 |
| 2026-07-07 | Horn Kinney | S (D) | 1,092 | $25 | 0 | Form 4 |
| 2026-07-07 | Barchas Isaac | S (D) | 16,906 | $24.2 | 108,504 | Form 4 |
| 2026-07-06 | Barchas Isaac | S (D) | 83,094 | $24.11 | 125,410 | Form 4 |
| 2026-07-02 | Lechleider Robert | M (A) | 55,000 | $8.73 | 70,805 | Form 4 |
| 2026-07-02 | Lechleider Robert | S (D) | 16,072 | $23.44 | 15,805 | Form 4 |
| 2026-07-02 | Lechleider Robert | S (D) | 16,214 | $22.76 | 31,877 | Form 4 |
| 2026-07-02 | Lechleider Robert | S (D) | 22,714 | $21.95 | 48,091 | Form 4 |
| 2026-07-02 | Barchas Isaac | S (D) | 75,665 | $22.35 | 232,839 | Form 4 |
| 2026-07-02 | Barchas Isaac | S (D) | 24,335 | $23.33 | 208,504 | Form 4 |
| 2026-06-30 | Barchas Isaac | S (D) | 101,050 | $21.12 | 308,504 | Form 4 |
Transaction codes in this quarter
Get IMNM insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1472012&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · IMNM company page · Immunome Inc. on SEC.gov
Questions
Are insiders buying or selling Immunome Inc. (IMNM)?
In Q3 2026, insiders at Immunome Inc. reported 29 non-derivative transactions on 15 Forms 3, 4 and 5: 0 open-market purchases and 16 sales worth $13.8M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Immunome Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/imnm.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.